DOSAGE REDUCTION OF LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH RENAL DYSFUNCTION: EFFECTS ON ANTI-XA LEVELS AND CLINICAL OUTCOMES

被引：0

作者：

Hornung, Paul ^{[1
]}

Khairoun, Meriem ^{[1
]}

Dekker, Friedo W. ^{[2
]}

Kaasjager, Karin A. H. ^{[3
]}

Huisman, Albert ^{[4
]}

Jakulj, Lily ^{[5
,6
]}

Bos, Willem Jan ^{[7
,8
]}

Rosendaai, Frits ^{[2
]}

Verhaar, Marianne ^{[1
]}

Ocak, Gurbey ^{[1
,2
,7
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, Utrecht, Netherlands

[2] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands

[3] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands

[4] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands

[5] Univ Amsterdam, Dianet Dialysis Ctr, Med Ctr, Amsterdam, Netherlands

[6] Dept Nephrol, Amsterdam, Netherlands

[7] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[8] Leiden Univ, Dept Internal Med, Med Ctr, Leiden, Netherlands

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

P0810

引用

页码：1141 / 1141

页数：1

共 50 条

[21] Anti-Xa levels with low molecular weight heparin calibrator can be used to exclude significant apixaban effect
Singh, J.
Ong, D. M.
Wallis, A.
Kelsey, G.
Tran, H.
[J]. PATHOLOGY, 2019, 51 (07) : 768 - 769
[22] THE ANTI-XA ACTIVITY OF DESMIN 370 IS ATTRIBUTABLE TO LOW-MOLECULAR-WEIGHT HEPARIN
BRIEGER, D
DAWES, J
[J]. THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1351 - 1351
[23] PARTIAL THROMBOPLASTIN TIME, ANTI-XA, AND LOW-MOLECULAR WEIGHT HEPARIN ADMINISTRATION
FREEDMAN, MD
HAYDEN, D
PRASAD, R
LEESE, PT
[J]. CLINICAL RESEARCH, 1989, 37 (01): : A103 - A103
[24] Description of anti-Xa monitoring practices during low molecular weight heparin use
Albert Lin
Sara R. Vazquez
Aubrey E. Jones
Daniel M. Witt
[J]. Journal of Thrombosis and Thrombolysis, 2019, 48 : 623 - 628
[25] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (Enoxaparin)
PerezRequejo, JL
LucenaSolano, O
PerezGarcia, M
Santarelli, MT
[J]. THROMBOSIS AND HAEMOSTASIS, 1997, : P1172 - P1172
[26] Stability of Plasma Anti-Xa Activity in Low-Molecular-Weight Heparin Monitoring
Rojnuckarin, Ponlapat
Akkawat, Benjaporn
Juntiang, Jumlong
[J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (03) : 313 - 317
[27] Low-molecular weight heparin (LMWH) in pregnancy: Role of anti-Xa monitoring
Abu-Hajir, M
Kuhlmann, RS
Wigton, TR
Friedman, KD
[J]. THROMBOSIS AND HAEMOSTASIS, 1999, : 846 - 846
[28] Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
Kovacs, MJ
Keeney, M
MacKinnon, K
Boyle, E
[J]. CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (01): : 55 - 60
[29] Low molecular weight heparin anti-Xa levels do not accumulate with extended duration therapy for venous thromboembolism in cancer patients.
Kovacs, MJ
McKinnon, KM
Morrow, BH
Keeney, M
[J]. BLOOD, 2001, 98 (11) : 269A - 269A
[30] Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin
Payne, S
Mackinnon, K
Keeney, M
Morrow, B
Kovacs, MJ
[J]. CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (05): : 317 - 319

← 1 2 3 4 5 →